Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:1538-1544, 2006
DOI: 10.2337/dc05-2370
© 2006 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hotta, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hotta, N.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Pathophysiology/Complications
Original Article

Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy

The 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial

Nigishi Hotta, MD1, Yasuo Akanuma, MD2, Ryuzo Kawamori, MD3, Kempei Matsuoka, MD4, Yoshitomo Oka, MD5, Motoaki Shichiri, MD6, Takayoshi Toyota, MD7, Mitsuyoshi Nakashima, MD8, Isao Yoshimura, PHD9, Nobuo Sakamoto, MD1, Yukio Shigeta, MD10 and the ADCT Study Group*

1 Chubu Rosai Hospital, Nagoya, Japan
2 Institute for Adult Diseases Asahi Life Foundation, Tokyo, Japan
3 Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan
4 Saiseikai Shibuya Satellite Clinic, Tokyo, Japan
5 Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Sendai, Japan
6 Research Institute of Lifestyle-Related Diseases, Osaka, Japan
7 Tohoku Rosai Hospital, Sendai, Japan
8 Hamamatsu Institute of Clinical Pharmacology and Therapeutics, Hamamatsu, Japan
9 Faculty of Engineering, Tokyo University of Science, Tokyo, Japan
10 Shiga University of Medical Science, Otsu, Japan

Address correspondence and reprint requests to Nigishi Hotta, MD, PhD, Chubu Rosai Hospital, 1-10-6 Komei, Minato-ku, Nagoya 455-8530, Japan. E-mail: hotta{at}chubuh.rofuku.go.jp

OBJECTIVE—We sought to evaluate the long-term efficacy and safety of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy.

RESEARCH DESIGN AND METHODS—Subjects with diabetic neuropathy, median motor nerve conduction velocity (MNCV) ≥40 m/s, and HbA1c ≤9% were enrolled in this open-label, multicenter study and randomized to 150 mg/day epalrestat or a control group. After excluding the withdrawals, 289 (epalrestat group) and 305 (control group) patients were included in the analyses. The primary end point was change from baseline in median MNCV at 3 years. Secondary end points included assessment of other somatic nerve function parameters (minimum F-wave latency [MFWL] of the median motor nerve and vibration perception threshold [VPT]), cardiovascular autonomic nerve function, and subjective symptoms.

RESULTS—Over the 3-year period, epalrestat prevented the deterioration of median MNCV, MFWL, and VPT seen in the control group. The between-group difference in change from baseline in median MNCV was 1.6 m/s (P < 0.001). Although a benefit with epalrestat was observed in cardiovascular autonomic nerve function variables, this did not reach statistical significance compared with the control group. Numbness of limbs, sensory abnormality, and cramping improved significantly with epalrestat versus the control group. The effects of epalrestat on median MNCV were most evident in subjects with better glycemic control and with no or mild microangiopathies.

CONCLUSIONS—Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, particularly in subjects with good glycemic control and limited microangiopathy.

Abbreviations: ADCT, Aldose Reductase Inhibitor-Diabetes Complications Trial • ARI, aldose reductase inhibitor • MFWL, minimum F-wave latency • MNCV, motor nerve conduction velocity • VPT, vibration perception threshold


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. A. Gleissner, J. M. Sanders, J. Nadler, and K. Ley
Upregulation of Aldose Reductase During Foam Cell Formation as Possible Link Among Diabetes, Hyperlipidemia, and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1137 - 1143.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. J.M. Boulton
Whither Clinical Research in Diabetic Sensorimotor Peripheral Neuropathy?: Problems of end point selection for clinical trials
Diabetes Care, October 1, 2007; 30(10): 2752 - 2753.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
G. J. Ryan
New pharmacologic approachesto treating diabetic retinopathy
Am. J. Health Syst. Pharm., September 1, 2007; 64(17_Supplement_12): S15 - S21.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. R. Drel, N. Mashtalir, O. Ilnytska, J. Shin, F. Li, V. V. Lyzogubov, and I. G. Obrosova
The Leptin-Deficient (ob/ob) Mouse: A New Animal Model of Peripheral Neuropathy of Type 2 Diabetes and Obesity
Diabetes, December 1, 2006; 55(12): 3335 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
Other articles noted
Evid. Based Med., October 1, 2006; 11(5): 159 - 160.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2006 by the American Diabetes Association.